• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Regulatory Update, January 2016

Regulatory Update, January 2016

January 1, 2016
CenterWatch Staff

FDA Seeks Comments on ICH’s GCP Guideline Update

In Sept. 29’s Federal Register, the FDA announced the availability of a draft guidance titled “Guideline for Good Clinical Practice” E6 (R2). The draft is an update of the International Conference on Harmonisation’s (ICH) “Guideline for Good Clinical Practice” E6 (R1), in which new information is integrated into the original document. The changes are intended to encourage improved and more efficient approaches to clinical trial design, conduct, oversight, recording, and reporting, and also to update standards regarding electronic records and essential documents. The draft also is intended to improve clinical trial quality and efficiency while maintaining human subject protection. The FDA made the draft guidance available for public comment on the sections added to ICH E6 (R1) and marked as “ADDENDUM.”

Regulatory authorities and industry associations have collaborated for years to promote international harmonization of regulatory requirements for pharmaceutical development and marketing. A major goal of harmonization is to identify and reduce differences in registration (marketing) requirements for drug development among different countries. ICH was organized to provide for tripartite harmonization initiatives among three regions: the European Union, Japan and the United States. Currently, ICH has eight sponsors: the European Commission; the European Federation of Pharmaceutical Industries Associations; the Japanese Ministry of Health, Labor, and Welfare; the Japanese Pharmaceutical Manufacturers Association; the FDA (with participation by its drug and biological product regulatory centers); the Pharmaceutical Research and Manufacturers of America; Health Canada; and Swissmedic.

Last June, ICH’s Steering Committee agreed to make the draft document available for public comment. When the document is made final, FDA will issue it as a final guidance document, as it did on May 9, 1997, with the original ICH GCP Guideline. Evolutions in technology and risk management processes offer new opportunities to increase clinical trial efficiency, in part by focusing on trial activities essential to ensuring human subject protection and the reliability of trial results. For example, the draft guidance recommends sponsors implement a system to manage quality throughout clinical trials and recommends sponsors develop a systematic, priority-based, risk-based approach to monitoring clinical trials. The draft guidance provides additional detail regarding recommendations for use of electronic trial data handling and remote electronic trial data systems.

FDA decided to end the comment period on Nov. 30 of last year. The European and Canadian authorities are allowing comments through Jan. 31. Therefore, sending in late comments (after Nov. 30) should still be considered by interested parties. Send written or electronic comments on the draft as instructed above and identify them with Docket No. FDA-2015-D-3327.

FDA Draft Guidance on Microbial Vectors Used for Gene Therapy

In Oct. 14’s Federal Register, the FDA announced the availability of a draft guidance titled “Recommendations for Microbial Vectors Used for Gene Therapy; Draft Guidance for Industry.” The draft provides investigational new drug application (IND) sponsors with recommendations concerning IND submissions for microbial vectors used for gene therapy (MVGTs) in early-phase clinical trials. MVGTs meet the regulatory definition of “biological product” when such products are applicable to the prevention, treatment, or cure of a disease or condition of human beings. The draft focuses on the chemistry, manufacturing, and control (CMC) information that sponsors should submit in an IND for MVGTs and provides an overview of preclinical and clinical considerations for these products. When made final, the document will supplement a guidance titled “Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs)” dated April 2008.

MVGTs include bacterial vectors such as Salmonella, Listeria or E. coli, genetically modified to express human tumor antigens, cytokines, growth factors, enzymes, therapeutic proteins, or nucleotides. MVGTs also may be generated by the modification (deletion, truncation, or point mutation) of chromosomal or episomal genes and by the insertion of foreign genetic material into the chromosome, or into naturally occurring episomes; or by the introduction of one or more plasmids. MVGTs may be microbes that are either live, replication-restricted (divided under specific growth conditions), capable of limited or no cell divisions, or killed, or a combination of those forms. In the April 2008 guidance, the FDA provided sponsors of a human gene therapy IND, including those with combination products that contain a human gene therapy biological product with a drug or device as part of the final product, with recommendations on CMC information that is to be included in an original IND. That guidance also provided instruction to the FDA’s CMC reviewers about the information to record and assess as part of an IND review.

Because last month’s due date of Dec. 14 passed before this issue of The CenterWatch Monthly was released, instructions on commenting are not provided here. Comments submitted by others were identified with Docket No. FDA-2015-D-3399. 

The Regulatory Update is excerpted from Research Practitioner, Volume 16, Number 6, November-December 2015. 

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing